HRT Financial’s BioLineRX BLRX Stock Holding History

HRT Financial’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-293	Closed	-$21K	–	2340
2023 Q3	$21K	Sell	293 -43	-13%	-$2.89K	﹤0.01%	2065
2023 Q2	$21K	Buy	+336	New	+$18.6K	﹤0.01%	2094

Other funds holding BLRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

VFA

Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial's BLRX Position: Q4 2023 in Review

HRT Financial sold out of BioLineRX (BLRX) in Q4 2023, closing a stake of 293 shares — an estimated $21K sold.

HRT Financial first reported a position in BLRX in Q2 2023 and held it in 2 quarters. The position peaked at $21K in Q3 2023. 29 funds tracked by Wall St. Rank hold BLRX as of Q4 2023.

HRT Financial reported no remaining BioLineRX position as of Q4 2023 after selling out during the quarter.
HRT Financial sold 293 BioLineRX shares in Q4 2023, an estimated $21K.
HRT Financial first reported a position in BioLineRX in Q2 2023 and held it in 2 quarters.
HRT Financial's BioLineRX position peaked at $21K in Q3 2023.
29 funds tracked by Wall St. Rank held BioLineRX as of Q4 2023.

Based on HRT Financial's 13F filing for Q4 2023, filed 9 Feb 2024.